Traditional Chinese Medicines and Drugs in Relation to the Host-Defense Mechanism

  • N. Satomi
  • A. Sakurai
  • R. Haranaka
  • K. Haranaka


Pseudomonas aeruginosa infection is observed mostly under immunosuppressive conditions. We have clarified that the combined use of antibiotics and specific antibodies is effective against mouse P. aeruginosa infection in vivo [1–5]. From our previous experiments, traditional Chinese medicines and crude drugs are known to cause stimulation of the reticuloendothelial system [6]. Kiger et al. [7] found that P. aeruginosa treatment (108 killed organisms) had a capacity to induce release of tumor-necrotizing factor in the serum of bacille Calmette-Guérin (BCG)-pretreated mice to the same extent as lipopolysaccharide (LPS) treatment. Our experiments on tumor necrosis factor (TNF) have demonstrated the production of TNF as well as its associated severe toxicity [8–10]. Recently, recombinant human TNF has been mass produced and many actions of this factor have become clear. We have found that by employing traditional Chinese medicines as priming agents, the toxic symptoms after administration of LPS could be reduced.


Tumor Necrosis Factor Chinese Medicine Pseudomonas Aeruginosa Traditional Chinese Medicine Crude Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Haranaka K, Sugane K, Mashimo K (1975) Combination therapy of anti-endotoxin antibody and gentamicin in the immunosuppressed mice with Pseudomonas aeruginosa infection. Jpn J Exp Med 45:207–213PubMedGoogle Scholar
  2. 2.
    Haranaka K, Matsuo M, Mashimo K (1977) The enhancement of phagocytosis and intracellular killing of Pseudomonas aeruginosa and its common antigen (OEP) coated latex particles by mouse spleen macrophages to which anti-OEP-IgG and gentamicin have been added. Jpn J Exp Med 47:35–40PubMedGoogle Scholar
  3. 3.
    Haranaka K, Satomi N, Sakurai A, Kunii O (1982) The combined use of antibiotics and specific antibodies against mouse Pseudomonas aeruginosa infection in vivo and the phagocytosis of peritoneal exudate cells in vitro. In: Eickenberg HU et al. (eds) The influence of antibiotics on the host-parasite relationship. Springer, Berlin Heidelberg New York, pp 161– 167CrossRefGoogle Scholar
  4. 4.
    Haranaka K, Matsuo M, Satomi N, Kunii O, Mashimo K (1978) The influence of anti-OEP-IgG and -IgM upon mouse spleen macrophage phagocytic activity against Pseudomonas aeruginosa and OEP-coated latex granules. J Jpn Infect Dis Soc 52:482–489Google Scholar
  5. 5.
    Haranaka K, Satomi N, Matsuo M, Kunii O, Mashimo K (1979) Therapeutic effects of anti-OEP-antibodies in the Psudomonas aeruginosa (Fisher’s seven serotypes) infection of mice and the influence of this antibody upon the phagocytic activity of mice spleen macrophages. J Jpn Infect Dis Soc 53:175–181Google Scholar
  6. 6.
    Haranaka K, Satomi N, Sakurai A, Haranaka R, Okada N, Kobayashi M (1985) Antitumor activities and tumor necrosis factor producibility of traditional Chinese medicines and crude drugs. Cancer Immunol Immunother 20:1–5PubMedCrossRefGoogle Scholar
  7. 7.
    Kiger N, Khalil A, Mathe G (1980) Tumor-necrotizing serum production by administration of BCG + Pseudomonas. Its application in treatment of fibrosarcoma in mice. Recent Results in Cancer Research (RRCR) 75:220–223Google Scholar
  8. 8.
    Haranaka K, Satomi N, Sakurai A, Kunii O (1985) Role of lipid A in the production of tumor necrosis factor and differences in antitumor activity between tumor necrosis factor and lipopolysaccharide. Tohoku J Exp Med 144:385–396CrossRefGoogle Scholar
  9. 9.
    Haranaka K, Satomi N, Sakurai A (1984) Differences in tumor necrosis factor productive ability among rodents. Br J Cancer 50:471–478PubMedCrossRefGoogle Scholar
  10. 10.
    Sakurai A, Satomi N, Haranaka K (1986) Differences in tumor necrosis factor productive ability among rabbits. Jpn J Exp Med 56:247–250PubMedGoogle Scholar
  11. 11.
    Haranaka K, Carswell EA, Williamson BD, Prendergast JS, Satomi N, Old LJ (1986) Purification, characterization, and antitumor activity of nonrecombinant mouse tumor necrosis factor. Proc Natl Acad Sci USA 83:3949–3953PubMedCrossRefGoogle Scholar
  12. 12.
    Muto S, Igarashi M, Matsumoto Y, Ogino H, Yuki H (1986) A simple and rapid method for the determination of macrophage activating factor involving a new type of apparatus suitable for the measurement of macrophage chemiluminescence. J Immunol Methods 90:51–56PubMedCrossRefGoogle Scholar
  13. 13.
    Sato K, Yamashita K, Okachi R (1985) In vivo combination effects of astromycin and ß-lactam antibiotics against Pseudomonas aeruginosa. Jpn J Antibiot 36:1487–1493Google Scholar
  14. 14.
    Suzuki I, Senda H (1985) In vivo activity of cefbuperazone (T-1982) against various experimental infections in mice. J Antibiot (Tokyo) 38:249–258Google Scholar
  15. 15.
    Oda T, Miyawaki T, Sameshima T, Miyao J (1984) Antishock effects of urinary trypsin inhibitor, MR-20 (in Japanese). Anesthesia 33:137–142Google Scholar
  16. 16.
    Yamamoto T, Okada H, Kuroiwa A (1985) Effects of Oriental herbal medicines on immunity in the elderly. In: Oda T et al. (eds) Recent advances in traditional medicine in East Asia. Excerpta Medica, Tokyo, pp 96–105Google Scholar
  17. 17.
    Maeda Y, Chihara G (1971) Lentinan, a new immuno-accelerator of cell-mediated responses. Nature 229:634PubMedCrossRefGoogle Scholar
  18. 18.
    Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72:3666–3670PubMedCrossRefGoogle Scholar
  19. 19.
    Haranaka K, Satomi N, Sakurai A (1984) Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer 34:263–267PubMedCrossRefGoogle Scholar
  20. 20.
    Shalaby MR, Aggarwal BB, Rindeknecht E, Svedersky LP, Finkle BS, Palladino MA Jr (1985) Activation of human polymorphonuclear neutrophil functions by interferon-y and tumor necrosis factors. J Immunol 135:2069–2073PubMedGoogle Scholar
  21. 21.
    Tsujimoto M, Yokota S, Vilcek J, Weissmann G (1986) Tumor necrosis factor provokes superoxide anion generation from neutrophils. Biochem Biophys Res Commun 137:1094–1110PubMedCrossRefGoogle Scholar
  22. 22.
    Beutler B, Milsark IW, Cerami AC (1985) Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229:869–871PubMedCrossRefGoogle Scholar
  23. 23.
    Satomi N, Sakurai A, Haranaka R, Haranaka K (1988) Preventive effects of several chemicals against lethality of recombinant human tumor necrosis factor. J Biol Response Mod 7:54–64PubMedGoogle Scholar
  24. 24.
    Haranaka K, Satomi N, Sakurai A, Haranaka R, Okada N, Kosodo H, Kobayashi M (1985) Antitumor activities and tumor necrosis factor producibility of traditional Chinese medicines and crude drugs. J Tradit Chin Med 5:271–278PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • N. Satomi
    • 1
  • A. Sakurai
    • 1
  • R. Haranaka
    • 2
  • K. Haranaka
    • 1
  1. 1.Department of Internal Medicine, Institute of Medical ScienceUniversity of TokyoMinato-ku, Tokyo 108Japan
  2. 2.Department of BiochemistryNihon University School of MedicineItabashi-ku, Tokyo 173Japan

Personalised recommendations